Clinical Trial Update: CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease [Phase 1]

View source ↗

Summary

Phase 1 study of CMV pp65-specific T cell adoptive immunotherapy in patients undergoing allogeneic stem cell transplantation for cancer; the trial was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CMV pp65-specific T cell adoptive immunotherapy

Snippet

Sponsor: H. Kim Lyerly | Conditions: Allogeneic Stem Cell Transplantation | Phase 1 | Status: TERMINATED